A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress)

BACKGROUND: Durvalumab is a standard drug used during maintenance therapy after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the clinical benefits of durvalumab after chemoradiotherapy in patients with LA-NSCLC with a perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaira, Kyoichi, Mouri, Atsuto, Kato, Shingo, Yoshimura, Kenichi, Kagamu, Hiroshi, Kobayashi, Kunihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542352/
https://www.ncbi.nlm.nih.gov/pubmed/33023530
http://dx.doi.org/10.1186/s12885-020-07406-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7542352/
https://www.ncbi.nlm.nih.gov/pubmed/33023530
http://dx.doi.org/10.1186/s12885-020-07406-y

Ejemplares similares